ADBE is showing a powerful move to the upside ahead of earnings.
Let's review the charts and indicators.
Here's what I'd look for this week and beyond.
Investors can now look to buy shares of this biotech firm.
Here's our strategy.
The shoes may be ugly, but the chart is attractive, and sales are good.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
Insider buying interest remains absent.
Traders could probe the long side at current levels.
The charts of the homebuilder aren't sending positive signals right now.